31 results
8-K
EX-99.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
that demonstrate the potential to harness the power of EMMs to tackle prevalent chronic conditions and I believe the company is now well positioned
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
outcome measure of fatigue that has been used in measuring subject impact in fatigue states such as chronic fatigue syndrome. The Clinical Trial
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
— Decreasing inflammation Axcella’s clinical data demonstrate the potential to harness the power of EMMs to tackle complex chronic conditions — Improving
8-K
bhvaz3
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
v71a8flxftaq thau0l
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
pnvtl
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
424B5
2vsqmud47qe
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
aa677j5 r6
10 Jan 22
Other Events
8:00am
8-K
EX-99.2
p489c
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
424B4
by8mh6 qarpumm
14 May 20
Prospectus supplement with pricing info
5:15pm